

**Application number**

1575647

**Type(s)**

Word

**Category**

Trademark

**CIPO Status**

ABANDONED SECTION 40(3)

**TM5 status**

DEAD/APPLICATION/  
Withdrawn/Abandoned



The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.

**Filed**

2012-04-30

**Applicant**

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285  
UNITED STATES OF  
AMERICA

**Documents**

[View documents](#)

**Index headings**

QESH

**Goods (Nice class & Statement)**

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol

**Classification data**

**Disclaimer**

The classification data is provided for information and searching purposes only. CIPO does not warrant the accuracy of the classes assigned to the trademark. This data has no legal value of any kind.

**Claims**

Priority Filing Date:

November 18, 2011, Country or Office: UNITED STATES OF AMERICA, Application No. 85476613 in association with the same kind of goods Proposed Use in CANADA

use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, namely osteoporosis, osteoarthritis, fracture healing, bone frailty due to extended ventilator use, hip replacement surgery and knee replacement surgery, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, arthritis, bursitis, tendonitis, osteonecrosis and Paget's disease, cancer, cardiovascular diseases, central nervous system diseases and disorders namely, anxiety disorders, depression, bipolar depression, bipolar disorder, treatment resistant depression, schizophrenia and cognitive impairment associated with schizophrenia, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, namely psoriasis, skin cancer and eczema, diabetes, dyslipidemia, endocrine diseases and disorders, namely Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, gastrointestinal diseases and disorders, hormonal diseases and disorders, namely vasomotor symptoms and hot flashes, inflammation and inflammatory diseases and disorders, namely inflammatory bowel diseases, inflammatory connective tissue diseases and rheumatoid arthritis, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, namely metabolic syndrome, migraines, muscle diseases and disorders, namely myopathies, chronic fatigue syndrome, fibromyalgia and muscular dystrophy, neurodegenerative diseases and disorders, namely Huntington's disease, Alzheimer's disease, Dementia and Parkinson's disease, neurological disorders namely, Alzheimer's disease, mild cognitive impairment, Parkinson's disease and multiple sclerosis, obesity, pain relief, pancreatic diseases and disorders, psychiatric disorders, namely acute stress disorder, substance abuse, delusions and hallucinations, reproductive system diseases and disorders, namely uterine fibroids, endometriosis, benign prostatic hyperplasia and polycystic ovarian syndrome, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants.  
5 - Pharmaceuticals and herbicides

**Action History**

Action	Action date	Due date	Comments
--------	-------------	----------	----------

Filed	2012-04-30		
Created	2012-05-01		
Formalized	2012-05-04		
Search Recorded	2012-07-16		
Approval Notice Sent	2012-07-16	2012-08-13	
Approved	2012-09-06		APPROVED BY PROGRAM EX200M1
Advertised	2012-09-12		Vol.59 Issue 3020
Allowed	2012-12-28		
Allowance Notice Sent	2012-12-28	2015-04-30	
Extension of Time	2015-03-31	2015-10-30	Online Request Date: 2015 /03/31
Extension of Time	2015-09-17	2016-04-30	Online Request Date: 2015 /09/17
Extension of Time	2016-03-08	2016-10-30	Online Request Date: 2016 /03/08
Extension of Time	2016-10-03	2017-04-30	Online Request Date: 2016 /10/03
Extension of Time	2017-04-04	2017-10-30	Online Request Date: 2017 /04/04
Extension of Time	2017-10-02	2018-04-30	Online Request Date: 2017 /10/02
Abandoned - Subsection 40(3)	2018-05-23		